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Abstract 
Gastroenterologists are intermittently involved in diagnosing and managing patients who have 
neuroendocrine tumours (NETs). However, few UK gastroenterologists have received extensive 
training about this topic. This article aims to provide a brief introduction to NETs; it is aimed at a 
general gastroenterologist audience.  
NETs present in diverse ways and many symptomatic patients unfortunately experience significant 
delays in diagnosis. Comprehensive evaluation of a patient with a possible NET involves assessing 
their symptoms, the tumour’s primary organ of origin, its differentiation status, grade and stage, 
whether the NET is secreting hormones and whether there is any underlying hereditary 
predisposition. Such assessment often needs specialist investigations such as nuclear medicine 
scans. All these factors influence patient management and prognosis, so a patient’s case and 
investigations should always be discussed by a fully constituted NET multi-disciplinary team. Most 
localised tumours are considered for resection, but there are multiple treatment options for 
metastatic disease and many patients receive several different therapies during the course of their 
illness. The most common first line treatment in patients who have metastatic low grade NETs is 
monthly long acting somatostatin analogue injections. Prognosis is highly variable, but some patients 
who have inoperable metastases survive for many years on treatment with good quality of life. 
Gastroenterologists may also be involved in managing the non-tumour associated chronic 
gastrointestinal problems that some patients experience. Their involvement has been shown to 
improve patient reported outcomes and quality of life. 
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Introduction – NETs are not as rare as you may think 
Neuroendocrine tumours (NETs) comprise a diverse set of relatively rare neoplasms. They arise at 
several locations within the body, but many of the most common primary sites involve the 
gastrointestinal tract and pancreas (hence the term gastroenteropancreatic (GEP)-NETs). GEP-NETs 
are therefore encountered periodically by most gastroenterologists during their routine clinical 
practice, but most of these clinicians would not consider themselves to be experts in this field. The 
aim of this article is to demystify the topic, so that practising general gastroenterologists can arrange 
appropriate initial investigations and can provide accurate information to their patients while they 
are being referred to NET specialists based at their regional multidisciplinary team (MDT). Its content 
has been influenced by the topics that were discussed by participants at a Frontline 
Gastroenterology Twitter debate on this topic in December 2019. The article is not aimed at 
clinicians who are already providing specialist care to NET patients and nuances of tertiary level care 
are beyond the scope of this review. We assume that definitive investigations and management will 
be undertaken by a specialist NET MDT. 
Although once considered rare, a recent epidemiological study reported a 6.4 fold increase in NET 
incidence between 1973 and 2012. This analysis of the US-based SEER database reported an annual 
age-adjusted incidence of 6.98 per 100,000 persons [1]. At least some of this increase in incidence is 
likely to have resulted from heightened awareness of the tumour type and enhanced detection by 
modern imaging and endoscopic techniques, but an actual real increase may also have contributed. 
As many patients who have NETs experience prolonged survival, even when they have metastatic 
disease (median overall survival 9.3 years), Dasari et al. also reported a 20-year limited-duration 
prevalence of 0.048% [1]. This prevalence (approximately 35 per 100,000) is higher than that of any 
other tumour arising within the GI tract with the exception of colorectal adenocarcinoma. A similar 
increase in incidence has also recently been reported in England, where the current age 
standardised incidence is 8.6 per 100,000 (4.6 per 100,000 for GEP-NETs) [2]. Recent Cancer 
Research UK statistics suggest that this overall UK age standardised incidence for NETs is only slightly 
lower than that of other cancers that many gastroenterologists assume to be more common such as 
gastric adenocarcinoma or hepatocellular carcinoma. These statistics imply that most general 
gastroenterologists will intermittently diagnose new cases of NET and, in addition, they are likely to 
regularly encounter patients who have established NET diagnoses. 
 
Terminology and Classification systems for NETs 
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One potentially confusing aspect of the NET field is the terminology that is employed, as this has 
changed substantially over recent years. The term neuroendocrine neoplasm (NEN) is now used to 
refer to all tumours of this type. Many of these tumours are well differentiated and slow growing 
with a relatively good prognosis (termed neuroendocrine tumours (NETs), table 1), whereas a 
minority are poorly differentiated and faster growing with a relatively poor prognosis (termed 
neuroendocrine carcinomas (NECs), table 1). Historically, NETs used to be described as ‘carcinoid 
tumours’, but in most countries, including the UK, this term is no longer used except for the NETs 
that arise in the lungs (bronchial carcinoids) and as part of the term ‘carcinoid syndrome’ (see 
below). Although technically inaccurate, we have sometimes used the abbreviation NET in this paper 
to refer to all NENs, as it is currently the more generally employed term. 
NETs can arise throughout the GI tract and pancreas, but the commonest sites are the small bowel, 
rectum, pancreas, stomach and appendix in decreasing order of frequency [1]. Tumour site is a 
major determinant of prognosis. For example, most appendiceal NETs have a very good prognosis. 
Tumour size is also an important prognostic factor for localised NETs at most sites. 
The most important feature in establishing a GEP-NET diagnosis is histology. This not only establishes 
the tumour type, but also influences treatment decisions and prognosis. Tissue for histopathological 
evaluation can be obtained via endoscopic or radiologically-guided biopsy or by surgical resection 
depending on the tumour site. A crucial feature is the establishment of a tumour’s grade (which is an 
indication of the proportion of NET cells that are proliferating at a particular time) by Ki67 
immunohistochemistry or mitotic count. NETs are currently classified as grades 1, 2 and 3 using Ki67 
cut-offs of <3%, 3-20% and >20% respectively. Grade 3 neoplasms are additionally subclassified into 
those which show well differentiated histology (NETs) and those which demonstrate poorly 
differentiated histopathological features (NECs) (table 1).  
Table 1: Classification of Neuroendocrine Neoplasms according to pathological differentiation and 
grade according to Ki-67 proliferation index 
Differentiation Ki-67 (%) Grade Classification of 
Neuroendocrine 
Neoplasm (NEN) 
Well differentiated <3 1 (G1) NET 
Well differentiated 3-20 2 (G2) NET 
Well differentiated >20, usually <55% 3 (G3) NET 
Poorly differentiated Usually >55% 3 (G3) NEC 
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In addition to establishing a tumour’s grade, tumour stage should be determined using conventional 
cross-sectional radiological imaging (CT and/or MR scan) and in many patients functional imaging 
techniques (see below). There are specific detailed TNM staging systems for NENs that arise at 
different anatomical sites, but as for most other GI tumours, stage I and 2 NENs are confined to the 
organ of origin, stage 3 NENs have lymph node metastases and stage 4 NENs have distant 
metastases (most commonly in the liver and bones). It is important to note that in contrast to most 
other GI cancers, some patients who have widespread stage 4 NETs have a relatively good prognosis, 
especially when the tumour is grade 1. 
The complete evaluation of a patient who has a NET also involves determining whether the tumour 
is secreting hormones or other bioactive compounds (i.e. whether it is functional (secretory) or non-
functional (non-secretory)). Functional tumours result in hormonally induced syndromes (e.g. 
carcinoid syndrome due to serotonin secretion from a metastatic small bowel NET or Zollinger 
Ellison syndrome due to gastrin hypersecretion from a pancreatic gastrinoma). The biochemical tests 
that are used to establish functionality are discussed below. 
Finally, consideration should be given as to whether there is any potential underlying reason why a 
patient has developed a GEP-NET. For example, some pancreatic NETs develop because a patient has 
a genetically predisposing condition such as multiple endocrine neoplasia (MEN) type I, von Hippel 
Lindau syndrome or neurofibromatosis type 1. Detecting the presence of one of these hereditary 
conditions has implications for therapy (e.g. it may affect the time at which pancreatic surgery is 
performed) as well as for screening other family members. 
Complete characterisation of a NEN therefore involves extensive investigations in order to establish 
its organ of origin, grade, differentiation status, stage, and functional status as well as the presence 
of any potential hereditary predisposing condition (e.g. the final diagnosis may be one of a sporadic 
non-functional, well differentiated, grade 1, stage 4 terminal ileal NET). 
 
Clinical presentation  
A small proportion of NET patients present with specific symptoms such as those caused by carcinoid 
syndrome (the classical triad of diarrhoea, flushing and wheezing). However, a much larger number 
of patients, particularly those with non-functional tumours, present with less specific symptoms 
such as change in bowel habit and/or abdominal pain. Some patients are even entirely 
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asymptomatic and their NET is detected incidentally while they are undergoing a scan or endoscopy 
to investigate an unrelated indication. The diagnosis of patients with NETs can therefore be very 
challenging.  
Despite a general increased awareness of GEP-NETs by clinicians, many patients still unfortunately 
experience considerable delays in diagnosis. This is often due to the non-specific nature of the 
symptoms that are often associated with GEP-NETs and the frequent overlap between these 
symptoms and those of other much commoner and less life threatening conditions such as irritable 
bowel syndrome (IBS). This may also be influenced by a perceived pressure in some cases to 
discharge patients with such symptoms who have a normal gastroscopy and/or colonoscopy. A 
recent international survey reported a mean patient-reported time from first symptom onset to NET 
diagnosis of 52 months [3]; while a recent survey that was initiated within the UK reported a median 
duration from the time of first symptoms to diagnosis of 36 months for small bowel NETs and 24 
months for pancreatic NETs [4]. Clinical features that may suggest a need for further investigations 
such as contrast enhanced abdominal CT scan may include new onset of symptoms in older patients 
in whom a new diagnosis of IBS is less likely, persistent symptoms (e.g. diarrhoea or abdominal pain), 
the presence of facial flushing or weight loss or any features suggestive of bowel obstruction. 
When NETs are strongly suspected on the basis of symptoms (e.g. features of carcinoid syndrome) or 
radiological investigations or when they have been diagnosed incidentally following histology, 
patients should be referred to a specialist NET multidisciplinary team (MDT) for comprehensive 
investigations and definitive management.  
 
Rational investigations  
a. Endoscopy 
GEP-NETs are frequently detected incidentally during upper or lower gastrointestinal endoscopy 
performed for other indications (Figure 1). The number, size and site of polyps should be recorded 
with capture of photographic imaging according to the BSG quality standards [5]. With gastric NETs, 
biopsies from surrounding normal gastric antral and corpus mucosa are essential to determine the 
type of gastric NET, the majority being type I gastric NETs associated with autoimmune atrophic 
gastritis and frequently pernicious anaemia with type III gastric NETs having the worst prognosis 
(Table 2) [6]. The majority of duodenal NETs diagnosed at endoscopy are non-functional. In a 
suspected duodenal gastrinoma, biopsies of gastric mucosa together with pH measurement of 
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gastric aspirate can be useful. Ideally endoscopy should be performed by a gastroenterologist with 
experience of NETs. Endoscopic polypectomy of gastric and duodenal NETs may need specialist 
advanced techniques such as EMR or ESD recognising the risk of perforation/haemorrhage 
(especially in the duodenum) and the appropriateness of ‘watch and wait’ in some cases [6]. 
Endoscopic resection should be undertaken as a planned procedure rather than at index endoscopy. 
This should not be undertaken in the small bowel where surgical resection is recommended instead. 
Often, small rectal NETs (with a yellow tinge and normal pit pattern) (Figure 1) can be misidentified 
as hyperplastic polyps where simple snare polypectomy may not be appropriate. Endoscopic 
ultrasound can therefore sometimes be helpful, especially with rectal NETs [7]. Rectal NET 
management is generally dependent on size as to whether endoscopic or surgical resection is 
performed according to ENETS guidelines (Figure 2)[7]. 
Table 2: Gastric NET classification and features 
Characteristic Type I Type II Type III 
Associated disease Chronic atrophic gastritis-
A and pernicious anaemia 
Zollinger Ellison 
syndrome and MEN-1 
None 
Proportion of tumours 80% 5% 15% 
Site of tumour Fundus/body Fundus/body 
(occasionally antrum) 
Antrum or 
fundus 
Number of tumours Multiple Multiple Single 
Size of tumour <1cm <1cm 2-5cm 
Plasma gastrin concentration High High Normal 
Gastric acid output Low High Normal 
Prognosis Good Good Poor 
 
b. Imaging 
After establishing a diagnosis of NET, most patients undergo cross sectional imaging of the thorax, 
abdomen and pelvis using CT and/or MRI. In addition, an 111In-octreotide scan or the more sensitive 
(and currently less generally available in the UK) 68Ga-DOTATATE PET-CT scan may be helpful (Figure 
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3). These functional imaging techniques are sometimes more sensitive for detecting the presence of 
metastases than conventional cross sectional imaging and additionally establish the somatostatin 
receptor status of the tumour. The latter is important for determining the suitability of some 
therapies. FDG-PET-CT scans can also sometimes be useful for staging, especially those patients with 
grade 3 NENs. Additional investigations to establish whether a NET is causing an extra-intestinal 
manifestation, such as echocardiography to determine whether a patient with carcinoid syndrome 
has carcinoid heart disease may also be indicated in certain patients. 
c. Biochemistry  
Biochemical tests are useful for establishing the functional status of a NET. However, in view of their 
specificity and sensitivity, they are of very limited use as a screening test for the presence of NETs, 
and their use in this setting is therefore not advocated. The serum/plasma concentration of the 
relatively non-specific biomarker chromogranin A is measured in most patients, but levels may be 
normal especially in small localised NETs and gastroenterologists should also be aware that 
conditions such as renal failure, inflammatory bowel disease and proton pump inhibitor use can 
sometimes cause false positive elevations. The fasting gut hormone test establishes the plasma 
concentrations of gastrin, somatostatin, glucagon and vasoactive intestinal peptide (VIP) and is 
helpful for characterising (mostly pancreatic) NETs. False positive elevations are however common, 
especially elevated gastrin concentrations as a result of acid suppressant medication use. Finally, the 
24 hour urinary (or in some hospitals plasma) concentration of 5-HIAA can be helpful in evaluating a 
patient who potentially has a metastatic small bowel NET and/or suspected carcinoid syndrome. 
However, gastroenterologists should again be aware of the multiple causes (including dietary) of 
false positive elevations of this test. Finally, the concentrations of NT-proBNP should be monitored 
in patients who have carcinoid syndrome as this is a useful biomarker for the presence of carcinoid 
heart disease. 
 
Treatment 
a. Principles of treatment 
The management of patients with NETs can be extremely complicated and ideally should take place 
after discussion in a regional NET MDT according to UKINETS/ENETS guidelines. Factors determining 
management include site of primary tumour, stage, grade, functionality of the tumour, site of 
metastases, availability of specialised investigations and treatments/surgery, patient fitness and 
choice, age and comorbidities. Management algorithms are too complex for this review due to the 
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heterogeneity of NETs, but ENETS and UKINETS have produced guidelines with comprehensive 
flowcharts [8, 9]. 
In principle, if a NET is localised and resectable, it should usually be resected (apart from small non-
functional duodenal NETs in the elderly, small non-functional pancreatic NETs, type I gastric NETs 
<15mm and some others, where there may be an argument for adopting a ‘watch and wait’ policy if 
tumours are also low grade). Even if a patient has a good prognosis and is relatively asymptomatic, 
but has a slow growing, low grade, localised small bowel NET, oncological resection can reduce the 
risk of desmoplasia in the future, and thus avoid potential inoperable small bowel obstruction and 
chronic gastrointestinal symptoms. Resection of small bowel tumours in particular should also be 
considered even in the presence of metastases. Obviously, life expectancy must be taken into 
consideration. If a NET is functional, particularly with the carcinoid syndrome, somatostatin 
analogue injections (lanreotide autogel or octreotide LAR which bind to somatostatin receptors) 
every four weeks reduce the symptoms that are caused by secreted peptides [8, 9]. Hepatic artery 
embolisation and Telotristat, a new tryptophan hydroxylase inhibitor [10] can also sometimes be 
useful for resistant symptomatic cases. 
b. Management of metastatic disease 
Somatostatin analogues are also the mainstay of treatment in the more common non-functional, 
unresectable, locally advanced or metastatic NETs of low/intermediate grade. Large randomised 
controlled trials, CLARINET [11] and PROMID [12], have demonstrated delayed tumour progression 
with these agents. Ideally, a 111In-octreotide scan or 68Ga-DOTATATE PET-CT scan is required to 
ascertain somatostatin receptor positivity prior to treatment. There is a role for hepatic resection 
(and/or radiofrequency ablation/embolisation) for synchronous or metachronous liver metastases in 
low or intermediate grade NETs in certain situations, but this should be discussed in a centralised 
NET MDT [8, 9]. Otherwise, the mainstay of treatment for locally advanced or metastatic disease is 
somatostatin analogues and a choice of chemotherapy or the tyrosine kinase inhibitors Sunitinib or 
Everolimus for the less common higher grade tumours, especially pancreatic NETs which are 
generally more aggressive. Whilst on treatment patients usually undergo imaging at intervals 
between 3 and 12 months to monitor for progression according to RECIST criteria. 
For midgut and pancreatic NET patients who have positive 111In-octreotide or 68Ga-DOTATAE PET-CT 
scans, if radiological progression is detected during first line treatment, Peptide Receptor 
Radionuclide Therapy (PRRT) is an effective and well tolerated second line treatment option [13]. 
This is given as several infusions over a year and consists of a somatostatin analogue labelled with a 
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radioactive component (177Lutetium-DOTATATE) that binds to somatostatin receptors, delivering the 
radioactive element internally to NET cells. 
Metastatic poorly differentiated tumours (NECs) are generally treated with platinum based 
chemotherapy (with palliative intent), but overall, unlike other cancers, chemotherapy is not very 
effective in the commoner lower grade and well differentiated NETs [14].  
Determinants of prognosis 
There are a number of factors which have been demonstrated to be prognostic in NET patients in 
addition to age and comorbidities. It is impossible to give a general overall prognosis for NETs due to 
their heterogeneity. Some patients with aggressive NECs only survive a few months from the time of 
diagnosis, while some patients who have stage IV metastatic small intestinal NETs can survive two 
decades with good quality of life on treatment [1]. The site of primary tumour is important with type 
I and II gastric, appendiceal and rectal NETs having excellent prognosis at similar stages compared to 
small intestinal and pancreatic NETs. NETs in the rectum appear to have the best prognosis, while 
NETs in pancreas have the highest risk of mortality. The US SEER data demonstrate hazard ratios 
(HRs) using the rectum with a median overall survival of 66 months as a reference of: pancreas 
median survival 27 months, HR, 2.034; small intestine, HR, 1.660; stomach, HR, 1.865) [15]. 
Grade as determined by Ki67% has repeatedly been shown to be prognostic with lower grade NETs 
having a better prognosis than higher grade NETs [16]. Stage is also prognostic with metastatic 
disease having worse prognosis than localised disease [16]. The US SEER data suggest a median 
overall survival of 54 months for localised disease compared to 10 months for distant disease for all 
neuroendocrine neoplasms [1]. However, compared to other GI cancers, several patients can have a 
relatively good prognosis on treatment even with widespread stage IV disease.  
 
The role of a gastroenterologist in managing NETs  
Gastroenterologists have a large part to play in the diagnosis and management of patients with NETs 
alongside other key specialities such as oncology, endocrinology, surgery, pathology, radiology, 
nuclear medicine and specialist nurses as part of a multidisciplinary team. The delayed diagnosis 
often found (24-36 months [4]) in particular with GEP-NETs (which comprise the majority of NETs) is 
often due to alternative diagnoses initially being made including Inflammatory Bowel Disease (IBD) 
and Irritable Bowel Syndrome (IBS) and is a worldwide problem without much improvement. 
Referral pathways suggest that Gastroenterologists and Gastrointestinal Surgeons are the 
predominant specialities making the diagnosis of NETs with increased awareness and education of 
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these specialities being shown to lead to a reduction in diagnosis time in Wales [17]. Many patients 
who have GEP-NETs essentially have a chronic gastrointestinal and hepatic disease with symptoms, 
‘flares’ and changes in imaging indicating a need for changes in management or surgery, analogous 
to models of care in IBD. Some patients have liver metastases and treatments that are used overlap 
with those used in hepatocellular cancer. Finally, during or after treatment, many patients 
experience chronic gastrointestinal symptoms from a number of causes which can impact quality of 
life. These may involve bile acid malabsorption, pancreatic insufficiency or small intestinal bacterial 
overgrowth and can be improved by the involvement of a Gastroenterologist [18]. The addition of 
Gastroenterologists as core members of the NET MDT is advised by ENETS and can improve patient 
outcomes [18], but unlike some European countries, gastroenterologists have historically had limited 
input with these patients in the UK and USA. 
 
Accessing more information and patient support 
Clinicians who are interested in obtaining more education or consulting guidelines about the 
management of NET patients are advised to consult the UKINETs (www.ukinets.org or Twitter 
@UKINETS) and ENETS (www.enets.org) websites for details, including training courses (e.g. NETs for 
newcomers) and conferences. Excellent patient information and support in the UK is provided by 
Neuroendocrine Cancer UK (www.netpatientfoundation.org) and locally by NET centres and their 
specialist nurses. www.livingwithnets.com also provides helpful patient information. 
 
Key points: 
1. The GI tract and pancreas are the commonest locations for neuroendocrine tumours (NETs), so 
these tumours are often first encountered by gastroenterologists. 
2. There are frequently considerable delays in diagnosing NETs, as symptoms may be similar to 
those found in other commoner conditions such as irritable bowel syndrome. 
3. Characterisation of a NET involves establishing a tumour’s grade, stage, primary site and 
secretory status and often requires specialist investigations. 
4. Tumour resection is usually advised for most localised NETs. 
5. Long acting somatostatin analogue injections represent the first line treatment option for most 
patients who have unresectable low grade NETs. 
6. There are multiple treatment options for NETs especially in the second line setting and these 
should be discussed by a fully resourced NET multidisciplinary team. 
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7. Patient prognosis varies greatly, but can be excellent in some patients who have widespread 
metastatic disease. 
8. Gastroenterologists play key roles in NET patient care from diagnosis to treatment and their 
involvement in a NET MDT improves the quality of patient reported outcomes and experience. 
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Figure legends 
Figure 1 Endoscopic images of (a) multiple type I gastric NETs with a background of atrophic gastritis 
and (b) a solitary rectal NET  
Figure 2 Algorithm for management of rectal NETs (adapted from ENETS Consensus Guidelines 
(Ramage et al Neuroendocrinology 2016;103:139–143) CT Computerised Tomography, EUS 
Endoscopic Ultrasound, G Grade, MRI Magnetic Resonance Imaging, NET Neuroendocrine, PET 
Positron Emission Tomography, Tumour SRS Somatostatin Receptor Scintigraphy, TME Total 
Mesorectal Excision 
Figure 3 68Ga-DOTATATE PET/CT scan demonstrating a large pancreatic NET with liver and nodal 
metastases as well as a bone metastasis in the right iliac crest. Note there is also physiological tracer 
uptake in the spleen, kidneys, bladder and pituitary gland. 
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